KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to -$331.0 million.

  • Biomarin Pharmaceutical's Cash from Investing Activities fell 194841.86% to -$331.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$295.4 million, marking a year-over-year decrease of 595801.89%. This contributed to the annual value of $136.5 million for FY2024, which is 22269.52% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Cash from Investing Activities of -$331.0 million as of Q3 2025, which was down 194841.86% from -$12.6 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Cash from Investing Activities high stood at $90.5 million for Q2 2024, and its period low was -$331.0 million during Q3 2025.
  • For the 5-year period, Biomarin Pharmaceutical's Cash from Investing Activities averaged around -$38.6 million, with its median value being -$29.7 million (2022).
  • Per our database at Business Quant, Biomarin Pharmaceutical's Cash from Investing Activities soared by 22400.69% in 2022 and then tumbled by 194841.86% in 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Cash from Investing Activities (Quarter) stood at -$55.4 million in 2021, then rose by 1.28% to -$54.7 million in 2022, then decreased by 18.74% to -$65.0 million in 2023, then skyrocketed by 217.61% to $76.4 million in 2024, then tumbled by 533.17% to -$331.0 million in 2025.
  • Its Cash from Investing Activities was -$331.0 million in Q3 2025, compared to -$12.6 million in Q2 2025 and -$28.2 million in Q1 2025.